Earnings Feed
Start Free
Home/Filings/4/0001225208-11-011388
4//SEC Filing

DZAU VICTOR J 4

Accession 0001225208-11-011388

CIK 0000732485other
View on SEC.govCompany Profile

Filed

Apr 5, 8:00 PM ET

Accepted

Apr 6, 2:03 PM ET

Size

75.6 KB

Accession

0001225208-11-011388

Insider Transaction Report

Form 4
Period: 2011-04-04
GENZYME CORPGENZ
DZAU VICTOR J
Director
Transactions
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+499.363→ 8,378.72 total
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+302.06→ 9,826.68 total
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+2,375→ 7,375 total
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+504.357→ 7,879.357 total
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+367.956→ 9,201.72 total
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+263.462→ 10,657.564 total
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−255.418→ 0 total
    From: 2008-06-30Exp: 2026-12-31→ Genzyme common stock (GENZ) (255.418 underlying)
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−455.044→ 0 total
    From: 2009-12-31→ Genzyme common stock (GENZ) (455.044 underlying)
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+322.9→ 9,524.62 total
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+255.418→ 10,912.982 total
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+198.394→ 11,318.942 total
  • Disposition from Tender

    Genzyme common stock (GENZ)

    2011-04-04$74.00/sh−2,550$188,700→ 0 total(indirect: By Trust)
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−263.462→ 0 total
    From: 2009-06-30→ Genzyme common stock (GENZ) (263.462 underlying)
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−504.357→ 0 total
    From: 2010-06-30→ Genzyme common stock (GENZ) (504.357 underlying)
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−367.956→ 0 total
    From: 2010-09-30→ Genzyme common stock (GENZ) (367.956 underlying)
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−322.9→ 0 total
    From: 2010-12-31→ Genzyme common stock (GENZ) (322.9 underlying)
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+286.546→ 10,113.226 total
  • Disposition to Issuer

    Genzyme common stock (GENZ)

    2011-04-04$76.01/sh−3,943.942$299,779→ 5,000 total
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−207.566→ 0 total
    From: 2008-03-31Exp: 2026-12-31→ Genzyme common stock (GENZ) (207.566 underlying)
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−499.363→ 0 total
    From: 2010-03-31→ Genzyme common stock (GENZ) (499.363 underlying)
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−198.394→ 0 total
    From: 2008-09-30Exp: 2026-12-31→ Genzyme common stock (GENZ) (198.394 underlying)
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−302.06→ 0 total
    From: 2008-12-31Exp: 2026-12-31→ Genzyme common stock (GENZ) (302.06 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2011-04-04−2,375→ 0 total
    Exercise: $0.00→ Genzyme common stock (GENZ) (2,375 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$46.24/sh−18,000$832,320→ 0 total
    Exercise: $46.24Exp: 2013-05-29→ Genzyme common stock (GENZ) (18,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$58.66/sh−7,500$439,950→ 0 total
    Exercise: $58.66From: 2010-05-21Exp: 2019-05-21→ Genzyme common stock (GENZ) (7,500 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$43.90/sh−9,000$395,100→ 0 total
    Exercise: $43.90From: 2005-05-27Exp: 2014-05-27→ Genzyme common stock (GENZ) (9,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$53.47/sh−3,000$160,410→ 0 total
    Exercise: $53.47From: 2002-05-31Exp: 2011-05-31→ Genzyme common stock (GENZ) (3,000 underlying)
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+455.044→ 8,833.764 total
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$51.52/sh−7,125$367,080→ 0 total
    Exercise: $51.52Exp: 2020-06-16→ Genzyme common stock (GENZ) (7,125 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$68.48/sh−7,500$513,600→ 0 total
    Exercise: $68.48From: 2009-05-22Exp: 2018-05-22→ Genzyme common stock (GENZ) (7,500 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$58.50/sh−14,000$819,000→ 0 total
    Exercise: $58.50From: 2007-05-25Exp: 2016-05-26→ Genzyme common stock (GENZ) (14,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$45.96/sh−1,010$46,420→ 0 total
    Exercise: $45.96From: 2004-05-29Exp: 2013-05-29→ Genzyme common stock (GENZ) (1,010 underlying)
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+280.876→ 10,394.102 total
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+207.566→ 11,120.548 total
  • Disposition to Issuer

    Genzyme common stock (GENZ)

    2011-04-04$74.00/sh−2,375$175,750→ 8,943.942 total
  • Disposition from Tender

    Genzyme common stock (GENZ)

    2011-04-04$74.00/sh−5,000$370,000→ 0 total
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−280.876→ 0 total
    From: 2009-03-31Exp: 2026-03-31→ Genzyme common stock (GENZ) (280.876 underlying)
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−286.546→ 0 total
    From: 2009-09-30→ Genzyme common stock (GENZ) (286.546 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$62.16/sh−15,000$932,400→ 0 total
    Exercise: $62.16From: 2008-05-24Exp: 2017-05-24→ Genzyme common stock (GENZ) (15,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$45.91/sh−890$40,860→ 0 total
    Exercise: $45.91From: 2004-05-29Exp: 2013-05-29→ Genzyme common stock (GENZ) (890 underlying)
Footnotes (3)
  • [F1]The phantom stock acquired under the Genzyme Directors? Deferred Compensation Plan was cancelled at the completion of the sanofi-aventis tender offer and converted into the right to receive a cash payment based on the closing price of Genzyme common stock on the last day it traded. Phantom stock was credited to the Reporting Person?s stock account under the deferred compensation at the end of each fiscal quarter from 1/1/2008 through 12/31/2010, pursuant to the Reporting Person?s plan election and the terms of the plan.
  • [F2]The vested restricted stock units were scheduled to vest on the date of the 2011 annual meeting of shareholders.
  • [F3]This option, which provided for vesting at the next annual meeting of shareholders, was cancelled upon the consummation of the sanofi-aventis tender offer in exchange for a payment representing (A) an amount of cash equal to the excess of $74.00 over the exercise price of the option, multiplied by the total number of shares subject to such options, and (B) one contingent value right (CVR) per cancelled option.

Documents

1 file

Issuer

GENZYME CORP

CIK 0000732485

→
Entity typeother

Related Parties

1
  • filerCIK 0001201252

Filing Metadata

Form type
4
Filed
Apr 5, 8:00 PM ET
Accepted
Apr 6, 2:03 PM ET
Size
75.6 KB
View on SEC.gov